Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system (Q36116539)

12 August 2017

1 reference

title

Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system (English)

1 reference

12 August 2017

main subject

prostatic hypertrophy

1 reference

based on heuristic

inferred from title

author

Martin Christian Michel

series ordinal

4

object named as

Martin C Michel

1 reference

12 August 2017

2

Richard P Koopmans

1 reference

12 August 2017

author name string

Maurits M Barendrecht

series ordinal

1

1 reference

12 August 2017

Jean J M C H de la Rosette

series ordinal

3

1 reference

12 August 2017

publication date

1 June 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

95 Suppl 4

1 reference

12 August 2017

page(s)

19-28

1 reference

Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

Alpha1-blocker therapy for lower urinary tract symptoms suggestive of benign prostatic obstruction: what are the relevant differences in randomised controlled trials?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

Use of alpha-blockers and the risk of hip/femur fractures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

Review of orthostatic tests on the safety of tamsulosin, a selective alpha1A-adrenergic receptor antagonist, shows lack of orthostatic hypotensive effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

Subtype specific regulation of human vascular alpha(1)-adrenergic receptors by vessel bed and age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

Effects of heat stress on baroreflex function in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

Treatment satisfaction of patients with lower urinary tract symptoms: randomised controlled trials vs. real life practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

A multicenter, community-based study of doxazosin in the treatment of concomitant hypertension and symptomatic benign prostatic hyperplasia: the Hypertension and BPH Intervention Trial (HABIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

Plasma catecholamines and essential hypertension. An analytical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

Association of hypertension with symptoms of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

Concentration-effect relationships and individual responses to doxazosin in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

Dose-titration study of alfuzosin, a new alpha 1-adrenoceptor blocker, in essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

Terazosin in benign prostatic hyperplasia: effects on blood pressure in normotensive and hypertensive men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

History of 7,093 patients with lower urinary tract symptoms related to benign prostatic hyperplasia treated with alfuzosin in general practice up to 3 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

Differential vascular alpha1-adrenoceptor antagonism by tamsulosin and terazosin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

Clinical pharmacology of alpha1A selective and nonselective alpha1-blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

Comparison of the antagonistic activity of tamsulosin and doxazosin at vascular alpha 1-adrenoceptors in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

Tamsulosin: real life clinical experience in 19,365 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

A single-blind study of doxazosin in the treatment of essential hypertension when added to nonresponders to angiotensin-converting enzyme inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

The addition of doxazosin to the treatment regimen of patients with hypertension not adequately controlled by by β-blockers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

The addition of doxazosin to the treatment regimen of hypertensive patients not responsive to nifedipine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

A 6-month large-scale study into the safety of tamsulosin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

Changes in ED therapy in the Viagra era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

Sildenafil-induced vasorelaxation is associated with increases in the phosphorylation of the heat shock-related protein 20 (HSP20).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

Cardiovascular effects of sildenafil citrate and recommendations for its use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors: a study with sildenafil and vardenafil

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

Combined oral therapy with sildenafil and doxazosin for the treatment of non-organic erectile dysfunction refractory to sildenafil monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

21 January 2018

Orthostatic hypotension

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

The relationship between orthostatic dizziness and hypotension in male medical students

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

Initiation of nonselective alpha1-antagonist therapy and occurrence of hypotension-related adverse events among men with benign prostatic hyperplasia: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

Prostatic tissual distribution of alfuzosin in patients with benign prostatic hyperplasia following repeated oral administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

Lower urinary tract symptoms suggestive of benign prostatic obstruction--what's the long-term effectiveness of medical therapies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05487.X

10.1111/J.1464-410X.2005.05487.X

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference